Drug prices and trends for TRIENTINE HCL

Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
TRIENTINE HCL 250 MG CAPSULE	16571-0810-01	2.30252	EACH	2026-07-22
TRIENTINE HCL 250 MG CAPSULE	31722-0683-01	2.30252	EACH	2026-07-22
TRIENTINE HCL 250 MG CAPSULE	43598-0459-01	2.30252	EACH	2026-07-22
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: February 16, 2026

Overview
Trientine HCl, marketed primarily under the brand name Syprine, is an oral chelating agent used to treat Wilson's disease, a genetic disorder causing excess copper accumulation. The drug gained approval from the U.S. Food and Drug Administration (FDA) in 1969. It is also marketed in other countries, often as a generic product, to manage copper overload where penicillamine is contraindicated or ineffective. The global demand centers around Wilson's disease management, with additional off-label applications under investigation.

Market Size and Demand Drivers

Wilson’s Disease Incidence

Estimated at 1 in 30,000 to 40,000 in the U.S.
Global prevalence approximates 50,000 to 70,000 cases
Diagnosis is primarily in young adults, with a slight female predominance

Current Adoption

Estimated U.S. prescriptions: 10,000–15,000 annually
In Europe and Asia, prescriptions are proportionally higher due to larger populations and varying diagnostic practices

Market Segments

Primary: Wilson’s Disease treatment
Secondary: Off-label uses in chelation therapy for other heavy metal poisoning
Future: Investigational use in neurodegenerative diseases linked to metal accumulation

Competitive Landscape

Main competitors include penicillamine (Cuprimine, Depen) and tetrathiomolybdate (experimental stage)
Trientine typically preferred in patients intolerant to penicillamine

Manufacturing and Supply

Several generic manufacturers operate globally
Supply chain depends on availability of raw materials and regulatory approvals

Pricing Dynamics

Current Pricing Range

Retail price for branded Trientine HCl (Syprine): approximately $10,000–$15,000 annually per patient ([2])
Generic versions: range from $2,000–$6,000 annually, depending on region and formulation
Price variation driven by insurance coverage, geographic location, and healthcare policies

Cost Components

Active pharmaceutical ingredient (API) cost: low to moderate
Manufacturing expenses for solid oral dosage forms: moderate
Regulatory and distribution costs: variable by region

Insurance and Reimbursement

Coverage in the U.S.: via Medicaid, Medicare, private insurers
Reimbursement limits influence patient out-of-pocket costs, impacting demand

Patent and Exclusivity Status

No active patents for Trientine HCl in the U.S.; patent expirations all occurred pre-2000
Market share shifting toward generic versions

Market Forecasts and Price Projections

Short-term (Next 2 Years)

Market growth driven by increased diagnosis rates and off-label use expansion
Price for branded drug: stable at $10,000–$15,000/year
Generics expected to fluctuate between $2,000–$6,000/year

Medium-term (3–5 Years)

Introduction of biosimilars or better formulations could exert downward pressure on prices
Patient access to cheaper generics will likely increase, reducing branded sales influence
Market volume projected compound annual growth rate (CAGR): approximately 3–5%

Long-term (5+ Years)

Potential entry of new chelators or gene therapies could disrupt current demand
Price reductions for generics: 10–20% over the next decade, aligned with typical generic market trends
Restricted due to chronic therapy necessity; prices tend to stabilize due to ongoing demand

Key Drivers and Risks

Drivers

Rising Wilson’s disease diagnosis globally
Increased awareness leading to earlier detection
Favorable regulatory stances for generic manufacturers

Risks

Development of more effective or targeted therapies
Changes in healthcare policies affecting drug reimbursement
Potential safety concerns or adverse events influencing prescribing patterns

Summary Table

Factor	Impact	Current Status	Projection
Global demand	Growth in Wilson’s disease cases	50,000–70,000 estimated patients worldwide	Mild to moderate growth
Pricing (brand)	High due to limited competition	$10,000–$15,000/year	Stable short-term
Pricing (generic)	Lower cost, competitive pressure	$2,000–$6,000/year	Slight decline in long-term
Competition	Increasing from generics, biosimilars	Several producers globally	Market share shifting
Regulatory environment	Facilitates generic entry	No patent protections since 2000	Continues to favor generics

Key Takeaways

Trientine HCl remains an essential treatment for Wilson's disease, with stable demand in the near-term.
Price trajectories will see modest declines due to generic competition and market saturation.
The combination of increasing diagnosis and off-label explorations sustains market volume.
Long-term threats include new therapies and regulatory changes, which could impact pricing and market share.

FAQs

1. What factors influence the price of Trientine HCl in different markets?
Pricing varies with regulatory approval status, generic availability, healthcare reimbursement policies, and regional economic factors. Branded versions are more expensive, while generics offer cost savings.

2. Are there any upcoming patent protections or exclusivity rights for Trientine HCl?
No, patent protections expired in the early 2000s, enabling generic manufacturers to produce lower-cost alternatives.

3. What are the primary competitors of Trientine HCl?
Penicillamine remains the most prescribed alternative, with experimental drugs like tetrathiomolybdate under investigation.

4. How could new therapies impact Trientine HCl’s market share?
Emergence of gene therapies or more effective chelators could decrease reliance on current drugs, affecting demand and pricing.

5. What countries represent the largest markets for Trientine HCl?
The U.S., Europe, and Japan are the primary mature markets. Emerging markets in Asia and Latin America also show increasing demand due to improved diagnosis.

References

[1] Wilson’s Disease Foundation. “Epidemiology and Diagnosis.” 2021.
[2] GoodRx. “Trientine Prices and Alternatives.” 2023.

Drug Price Trends for TRIENTINE HCL

Average Pharmacy Cost for TRIENTINE HCL

Market Analysis and Price Projections for Trientine HCl